Optimizing combination approaches

In the race to find new oncology treatments, solid tumor clinical trials are continuing to pave the way in the discovery and approval of effective new anti-cancer therapies, including combination immunotherapies and other forms of innovative targeted approaches.

 

 

Optimized Approaches to Immunotherapy
 

Syneos Health® has been involved in supporting clinical and/or commercial services for six out of the seven checkpoint inhibitors currently on the market.

Our total solid tumor immunotherapy experience in the last five years spans 161 studies involving more than 18,000 patients in a variety of solid tumor subtypes.

This experience is diverse involving a breadth of immuno-oncology therapies and mechanisms of action, including 69 studies with checkpoint inhibitors (CPIs) and 26 studies with genetically modified organisms (GMOs).

 

Read the Full Report Here

Contact Us
Call Our Team 

Phone: +1 919 876 9300
Fax: +1 919 876 9360
Toll-Free: +1 866 462 7373

Corporate Headquarters

1030 Sync Street
Morrisville, NC 27560 USA